Sugi Predict

Sugi Predict / Compounds / SCHEMBL2507487

SCHEMBL2507487

SCHEMBL2507487

O=[N+]([O-])c1cccc(F)c1NC1CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.44
▸ GAA P10253 2/20 0.44
▸ GLA P06280 1/20 0.44
▸ HCAR3 P49019 3/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ L3MBTL1 Q9Y468 2/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ MAPK1 P28482 3/20 0.40
▸ TDP1 Q9NUW8 2/20 0.40
▸ GPR35 Q9HC97 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ LMNA P02545 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ CYP1A2 P05177 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14249826 0.93 GSK3A (0.45) MAPTGAAGLAHCAR3MEN1
SCHEMBL14314232 0.93 GSK3A (0.45) MAPTGAAGLAHCAR3MEN1
SCHEMBL14316049 0.84 ALDH1A1 (0.35) MAPTGAAGLAHCAR3MEN1
SCHEMBL14316053 0.84 ALDH1A1 (0.35) MAPTGAAGLAHCAR3MEN1
SCHEMBL14250455 0.82 KMT2A (0.40) MAPTGAAHCAR3MEN1KMT2A
SCHEMBL14250456 0.82 KMT2A (0.40) MAPTGAAHCAR3MEN1KMT2A
SCHEMBL16787436 0.81 ALDH1A1 (0.45) MAPTGAAHCAR3MEN1KMT2A
SCHEMBL20337755 0.81 MAPT (0.47) MAPTGAAGLAHCAR3MEN1
SCHEMBL16787429 0.81 SMN1; SMN2 (0.51) MAPTHCAR3KMT2AL3MBTL1ALDH1A1
SCHEMBL2504369 0.81 HCAR3 (0.42) MAPTGAAGLAHCAR3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260097034-A1 METALLOENZYME INHIBITOR COMPOUNDS CORXEL PHARMACEUTICALS HONG KONG LTD (HK) 2026-04-09 — — US disclosed
US-12458642-B2 Metalloenzyme inhibitor compounds CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) 2025-11-04 — — US disclosed
EP-4311577-A2 METALLOENZYME INHIBITOR COMPOUNDS Ji Xing Pharmaceuticals Hong Kong Limited (HK) 2024-01-31 — — EP disclosed
EP-3562487-B1 METALLOENZYME INHIBITOR COMPOUNDS JI XING PHARMACEUTICALS HONG KONG LTD (HK) 2023-11-29 — — EP disclosed
US-20210322409-A1 METALLOENZYME INHIBITOR COMPOUNDS SELENITY THERAPEUTICS (BERMUDA), LTD. (BM) 2021-10-21 — — US disclosed
US-20210322409-A1 METALLOENZYME INHIBITOR COMPOUNDS SELENITY THERAPEUTICS (BERMUDA), LTD. (BM) 2021-10-21 — — US disclosed
US-11040034-B2 Metalloenzyme inhibitor compounds PHASEBIO PHARMACEUTICALS, INC. (US) 2021-06-22 — — US disclosed
US-11040034-B2 Metalloenzyme inhibitor compounds PHASEBIO PHARMACEUTICALS, INC. (US) 2021-06-22 — — US disclosed
CN-110691598-A Metalloenzyme inhibitor compounds 赛列尼蒂治疗(百慕大)有限公司 2020-01-14 — — CN disclosed
EP-3562487-A2 METALLOENZYME INHIBITOR COMPOUNDS Selenity Therapeutics (Bermuda), Ltd. (BM) 2019-11-06 — — EP disclosed
WO-2018125800-A2 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS (BERMUDA), LTD. (BM) 2018-07-05 — — WO disclosed
US-20180185362-A1 METALLOENZYME INHIBITOR COMPOUNDS CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) 2018-07-05 — — US disclosed
US-8575183-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2013-11-05 — — US disclosed
US-8575183-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2013-11-05 — — US disclosed
US-8575183-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2013-11-05 — — US disclosed
EP-2552908-A2 HETEROCYCLIC COMPOUNDS AND THEIR USES Amgen Inc. (US) 2013-02-06 — — EP disclosed
WO-2011123751-A2 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2011-10-06 — — WO disclosed
WO-2011123751-A2 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2011-10-06 — — WO disclosed
US-20110245257-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2011-10-06 — — US disclosed
US-20110245257-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2011-10-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12458642-B2 Metalloenzyme inhibitor compounds CYP11B2, CYP11B1, HSD11B2 MAPT 2593/4885GAA 139/4885GLA 1014/4885
US-20180185362-A1 METALLOENZYME INHIBITOR COMPOUNDS SOD1, RNASE1, FECH MAPT 2388/4885GAA 4/4885GLA 485/4885
US-20260097034-A1 METALLOENZYME INHIBITOR COMPOUNDS CPN1, TPP1, DPP4 MAPT 2173/4885GAA 5/4885GLA 581/4885
US-20210322409-A1 METALLOENZYME INHIBITOR COMPOUNDS SOD1, RNASE1, FECH MAPT 2388/4885GAA 4/4885GLA 485/4885
US-11040034-B2 Metalloenzyme inhibitor compounds SOD1, RNASE1, FECH MAPT 2388/4885GAA 4/4885GLA 485/4885
US-20110245257-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, BCL9, MALT1 MAPT 3355/4885GAA 2664/4885GLA 2273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.